节点文献

肝癌TACE还是HAIC?

Treatment of hepatocellular carcinoma: TACE or HAIC?

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 杜楠王英李文涛

【Author】 DU Nan;WANG Ying;LI Wentao;Department of Interventional Radiology,Affiliated Cancer Hospital of Fudan University;Department of Oncology,Shanghai Medical College of Fudan University;

【通讯作者】 李文涛;

【机构】 复旦大学附属肿瘤医院介入治疗科复旦大学上海医学院肿瘤学系

【摘要】 经导管动脉化疗栓塞术(TACE)是目前中晚期不可切除肝癌的常用治疗方法。近年来,国内奥沙利铂+氟尿嘧啶+亚叶酸钙(FOLFOX)方案的肝动脉灌注化疗(hepatic artery infusion chemotherapy, HAIC)已用于治疗中晚期肝癌。HAIC联合应用分子靶向药物和(或)免疫检查点抑制剂,取得了令人鼓舞的成果。该文介绍了TACE和HAIC的理论基础、发展史及研究进展,分析比较二者的疗效和不良反应,以期为中晚期肝癌患者选择治疗时机及治疗方案提供参考。

【Abstract】 At present, transcatheter arterial chemoembolization(TACE) is a common treatment for advanced unresectable hepatocellular carcinoma(HCC).In recent years, hepatic artery infusion chemotherapy(HAIC) with oxaliplatin plus fluorouracil and leucovorin(FOLFOX) regimen has been used in the treatment of advanced HCC in China.HAIC in combination with molecular targeted drugs and/or immune checkpoint inhibitors has yielded encouraging results.This paper aims to describe the theoretical basis, development history and research progress of TACE and HAIC,to analyze and compare the efficacy and adverse events of TACE and HAIC,so as to provide a reference for the choice of treatment timing and therapeutic regimen for patients with advanced HCC.

  • 【文献出处】 介入放射学杂志 ,Journal of Interventional Radiology , 编辑部邮箱 ,2024年12期
  • 【分类号】R735.7
  • 【下载频次】170
节点文献中: 

本文链接的文献网络图示:

本文的引文网络